Back to Authors

Patel, Parita

https://orcid.org/0000-0003-3969-9026

Mayo Clinic

Northwestern University

Citations 2

Indeterminate etiology of acute liver failure in North America: Less common, still grave prognosis
Patel, Parita , Livingston, Sherry , Rakela, Jorge , Stravitz, R. Todd , Reuben, Adrian , Bass, Nathan M., Tujios, Shannan R. , Larson, Anne M. , Sussman, Norman , Durkalski‐Mauldin, Valerie, Lee, William M. , Ganger, Daniel , (ALFSG), the Acute Liver Failure Study Group, Patel, Parita V , Rakela, Jorge , Rule, Jody A. , (ALFSG), the Acute Liver Failure Study Group

Clinical Transplantation | September 14, 2023 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/ctr.15128 Get It

AbstractBackgroundThe etiology of acute liver failure (ALF) remains one of the most important factors in determining prognosis and predicting outcomes. In a significant proportion of ALF cases, however, the etiology remains unknown and is categorized as indeterminate ALF (IND‐ALF). In this study, we summarize findings from patients with IND‐ALF from 32 transplant centers across the United States, and we compare laboratory, prognostic, and outcome data for patients with IND‐ALF.MethodsBetween 1998 and 2019, 3364 adult patients with ALF or acute liver injury (ALI) from 32 liver transplant centers were enrolled in the ALFSG registry. The primary clinical outcome of interest was 21‐day transplant‐free survival (TFS).ResultsOf the 3364 patients enrolled in the ALFSG registry, 3.4 % (n = 114) were adjudicated as true indeterminate. On multivariate analysis, patients with a lower bilirubin, lower INR, lack of use of mechanical ventilation and no clinical features of coma at baseline had a higher odds ratio of transplant free survival. The number of deaths were similar between patients with true‐IND ALF versus patients with indeterminable ALF (29.8% vs. 27.2%), with almost half of the patients requiring liver transplant (42.1% vs. 45.7%).ConclusionWe illustrate the poor prognoses that true‐IND‐ALF and indeterminable ALF carry and the need for emergency liver transplantation in most cases.
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy
Patel, Parita , Yarur, Andrés , Dalal, Sushila , Sakuraba, Atsushi , Hanan, Ira M., Raffals, Laura H., Cohen, Russell D. , Pekow, Joel , Sakuraba, A , Rubin, David T. , Hanauer, Stephen B. , Yarur, Andres J , Pekow, Joel

Inflammatory Bowel Diseases | March 1, 2018 | Volume: 24 | Issue: 6 | Pages: 1291-1297

10.1093/ibd/izx105 Get It

Abstract Background IV ciclosporin therapy is effective in steroid-refractory ulcerative colitis. The optimal drug level to achieve response and minimize complications during induction therapy is not known. Aim The primary aim was to evaluate if serum ciclosporin drug levels are associated with increased risk of colectomy within 90 days of hospitalization. Secondary aims were to determine if ciclosporin levels are associated with avoidance of colectomy at 7 and 30 days, if ciclosporin levels are associated with drug-related and postoperative complications, and if patient-specific factors are associated with response to ciclosporin. Methods We conducted a retrospective analysis of 81 hospitalized patients with steroid-refractory ulcerative colitis treated with ciclosporin. Risk factors for colectomy within 7, 30, and 90 days, medication-specific and postoperative complications were compared by first, mean, and peak ciclosporin level during IV induction therapy. Results There were 47 patients (58%) who underwent surgery. There were no differences between initial, mean, and peak ciclosporin levels among responders and nonresponders and treatment-related or postoperative complications. Responders within 90 days had lower C-reactive-protein levels (20mg/L vs. 38mg/L, P = 0.01), lower serum albumin concentrations (3.4g/dL vs. 3.7g/dL, P = 0.03), and higher rates of kidney injury (50% vs 17%, P = 0.002). Conclusion Initial, mean, and peak serum levels of ciclosporin did not correlate with response or toxicity. However, C-reactive-protein levels levels and kidney injury may be helpful in predicting clinical response to ciclosporin.